Matrix Asset Advisors Inc. NY Sells 616 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Matrix Asset Advisors Inc. NY lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 99,495 shares of the medical equipment provider’s stock after selling 616 shares during the period. Matrix Asset Advisors Inc. NY’s holdings in Zimmer Biomet were worth $10,740,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Zimmer Biomet by 12.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider’s stock worth $1,404,638,000 after acquiring an additional 1,215,935 shares during the last quarter. American Century Companies Inc. raised its holdings in Zimmer Biomet by 12.6% during the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider’s stock worth $701,521,000 after purchasing an additional 722,041 shares during the last quarter. Boston Partners lifted its position in Zimmer Biomet by 26.3% during the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider’s stock valued at $437,413,000 after purchasing an additional 691,191 shares during the period. Magnetar Financial LLC boosted its stake in shares of Zimmer Biomet by 58.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider’s stock valued at $142,203,000 after purchasing an additional 484,816 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Zimmer Biomet by 329.2% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 490,138 shares of the medical equipment provider’s stock worth $53,195,000 after buying an additional 375,929 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. UBS Group reduced their price objective on shares of Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research note on Thursday, August 8th. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Tuesday, September 17th. Canaccord Genuity Group cut their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Wolfe Research started coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating for the company. Finally, Morgan Stanley cut their price target on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Monday, July 15th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $124.53.

Zimmer Biomet Stock Up 0.7 %

Shares of Zimmer Biomet stock opened at $103.50 on Friday. The firm has a market cap of $21.29 billion, a PE ratio of 22.40, a P/E/G ratio of 1.89 and a beta of 1.02. The business’s 50 day simple moving average is $108.37 and its 200 day simple moving average is $113.21. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.63 and a current ratio of 1.29. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The firm’s revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $1.82 earnings per share. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post 8 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.93%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.